©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2023; 11(6): 1372-1378
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1372
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1372
Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report
Moinard-Butot Fabien, Poprawa Elodie, Benabdelghani Meher, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France
Schohn Anna, Department of Supportive Care, Institut de cancérologie Strasbourg Europe, Strasbourg 67200, France
Pietro Addeo, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Hôpitaux Universitaires de Strasbourg, Strasbourg 67200, France
Author contributions: Moinard-Butot F and Benabdelghani M Writing original draft preparation; Moinard-Butot F, Poprawa E and Schohn A performed visualization; Moinard-Butot F, Poprawa E, Schohn A, Addeo P and Benabdelghani M writing review and editing; all authors have read and agreed to the published version of the manuscript.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Moinard-Butot Fabien, MD, Doctor, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg 67200, France. f.moinard-butot@icans.eu
Received: October 29, 2022
Peer-review started: October 29, 2022
First decision: January 12, 2023
Revised: January 17, 2023
Accepted: February 2, 2023
Article in press: February 2, 2023
Published online: February 26, 2023
Processing time: 117 Days and 18.6 Hours
Peer-review started: October 29, 2022
First decision: January 12, 2023
Revised: January 17, 2023
Accepted: February 2, 2023
Article in press: February 2, 2023
Published online: February 26, 2023
Processing time: 117 Days and 18.6 Hours
Core Tip
Core Tip: Gemcitabine is known for vascular side effect. In this case, we report a vascular acrosyndrome that occurred during first-line with Gemcitabine for pancreatic adenocarcinoma. In this case, the patient experienced prolonged tumor response. Immunological phenomena could be responsible for this double effect.